Element 8.17
Genomic and pharmacogenomic medicine
- Sheet
- 8.17
- Chapter
- 8 Health and care
- State
- Drafted
- Release
- 16 November 2026
- Editor
- Contributed by Praecise as open research
- Reviewers
- To be named at review
- Safety
- S3, as the chapter
- Licence
- CC BY-SA 4.0
- Resources
- 7
The element
- Requirement
Where genetic testing is offered to members, it is ordered and interpreted by qualified clinicians, linked to published guidelines, held privately, and shared only with consent. This page describes how a community organises; it gives no medical advice, dosage or diagnosis.
- How to tell
The provider can name the guidelines it uses. For pharmacogenomics, which uses a person's genes to guide the choice of medicines, the Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes gene-drug guidelines (CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network); its curated content is released under CC0 with a request for attribution (CPIC data (Clinical Pharmacogenetics Implementation Consortium)). Genetic results are held by the provider under the data rules in 8.8.
- Options
Pharmacogenomic testing through the provider. In a cluster-randomised trial across 18 hospitals, nine community health centres and 28 community pharmacies in seven European countries, a 12-gene panel guiding prescribing under Dutch guidelines was followed by fewer clinically relevant adverse drug reactions: 21.0% against 27.7% among patients with an actionable result (A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study).
Diagnostic and newborn genetic testing. Through the national service, where it exists.
Gene therapies. Given only in specialised centres. In December 2023 the FDA approved Casgevy, its first approved therapy using CRISPR/Cas9, and Lyfgenia, for sickle cell disease in patients 12 and older (FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease).
Consumer tests. Outside clinical care; results raise privacy questions.
- Settled, open, contested
Settled. Guideline-based pharmacogenomic prescribing reduced adverse reactions in a large trial (A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study). Sequencing has become far cheaper: NHGRI's retrospective estimates fall from hundreds of millions of dollars for the first reference genome to below 1,500 US dollars for a draft genome in late 2015, its latest figure on a page last updated in 2021 (The Cost of Sequencing a Human Genome).
Open. Long-term outcomes and access to gene therapies outside rich health systems. No source opened in this work gives prices with dates.
Contested. Whether to test everyone in advance or only when a medicine is to be prescribed. The PREPARE trial tested before prescribing (A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study); no source opened here settles pre-emptive population testing.
The four stages
Learn: what pharmacogenomic guidelines are (CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, CPIC data (Clinical Pharmacogenetics Implementation Consortium)) and WHO's case for wider access to genomics, which sets out fifteen actions (Accelerating access to genomics for global health: promotion, implementation, collaboration, and ethical, legal, and social issues). Design: a privacy rule for genetic data, informed by the CARE principles where Indigenous data is concerned (The CARE Principles for Indigenous Data Governance). Build: nothing on site; testing is by laboratories. Deploy: results kept with the provider and the person.
Resources at each stage
1 Learn
Understand
- The CARE Principles for Indigenous Data Governance Framework, S0
- CPIC data (Clinical Pharmacogenetics Implementation Consortium) Repository, S3
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network Paper, S2
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease Case study, S3
- The Cost of Sequencing a Human Genome Guide, S0
- A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study Paper, S3
- Accelerating access to genomics for global health: promotion, implementation, collaboration, and ethical, legal, and social issues Guide, S1
What changes between 30 adults and 300 people
For 30 adults and for 300 people alike, testing is individual and through providers. With 300 people, families and relatives within the community make privacy rules more important: one person's result says something about relatives.
Reference designs
Open for contributions Designs with drawings, specifications and a bill of materials. Add to it
Parts list
Every resource that supports this element. Those marked External carry the label “External resource. Not made or verified by Public Protocol”.
Depends on, and completes
It is one of 22 elements that complete Health and care.
The standing questions
Who pays for tests. Who holds the results. Who decides whether relatives are told: the person tested, with their clinician.
Environments
No source found on how genomic medicine changes by setting for islands and coasts, Arctic cold, hot deserts, tropical humid forest, temperate forest, high altitude, flood plains or other harsh settings.
Safety
State and evidence
Drafted
An editor has written the element's text from the resources listed under it, citing them. It is checked when it is reviewed.
Evidence from a real place or system is recorded here, with what did not work. What the states mean
History
- Drafted in the release of 16 November 2026.